QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 orgenesis-q3-eps-193-down-from-012-yoy-sales-34700k-up-from-11000k-yoy

Orgenesis (NASDAQ:ORGS) reported quarterly losses of $(1.93) per share. This is a 1508.33 percent decrease over losses of $(0.1...

 why-orgenesis-orgs-stock-is-down-23-today

Orgenesis shares are trading lower by 23% during Monday's session. The company announced a 1-for-10 reverse stock split.

 orgenesis-announces-results-from-a-real-world-study-of-org-101-car-t-therapy-in-patients-with-cd19-acute-lymphoblastic-leukemia-top-line-efficacy-and-safety-data-from-the-study-had-a-complete-response-of-82-in-adult-patients-and-93-in-pediatric-patients

Orgenesis' CD19 CAR-T therapy, ORG-101, had a complete response (CR) of 82% in adults and 93% in pediatric patients with th...

 orgenesis-announces-strategic-partnership-with-harley-street-healthcare-group-to-launch-a-longevity--wellness-initiative-globally-orgenesis-and-hshg-will-establish-a-jv-with-orgenesis-owning-49-and-hshg-owning-51-of-the-entity-hshg-has-agreed-to-invest-up-to-10m-over-3-years-into-orgenesis-and-the-joint-venture

Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the ful...

 correction-orgenesis-q2-eps-loss-of-023-up-from-076-yoy-sales-24600k-up-from-11300k-yoy

Orgenesis (NASDAQ:ORGS) reported quarterly losses of $(0.23) per share. This is a 69.74 percent increase over losses of $(0.76)...

 orgenesis-entered-purchase-deal-with-theracell-for-purchase-of-50-outstanding-ownership-rights--equity-interests-in-theracell-laboratories-ike-pursuant-to-deal-for-purchase-of-assets-co-to-pay-theracell-13m

- SEC Filing

 orgenesis-q1-eps-029-down-from-017-yoy-sales-14100k-miss-1200m-estimate

Orgenesis (NASDAQ:ORGS) reported quarterly losses of $(0.29) per share. This is a 270.59 percent decrease over earnings of $0.1...

 orgenesis-inc-files-for-mixed-shelf-of-up-to-100m--sec-filing

- SEC Filing

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION